News

Tiziana Life Sciences has received fast track designation from the U.S. Food and Drug Administration (FDA) for its intranasal foralumab to treat nonactive secondary progressive multiple sclerosis (SPMS). The FDA gives fast track status to experimental medicines that have the potential to fill unmet needs to treat serious…

Iaso Biotherapeutics has received the green light from the U.S. Food and Drug Administration (FDA) to start clinical trials of its investigational CAR T-cell therapy equecabtagene autoleucel (eque-cel) in people with multiple sclerosis (MS). The FDA’s clearance of the company’s investigational new drug (IND) application makes MS the…

Inflammation outside of the brain and spinal cord, which can be caused by infections like the common cold, flu, or urinary tract infections (UTIs), is associated with more damage to the nervous system in people with progressive forms of multiple sclerosis (MS). That’s according to the study “…

The National Multiple Sclerosis Society (NMSS) said it named Tim Coetzee, PhD, president and chief executive officer. Coetzee had been chief advocacy, services, and science officer for the organization, which provides funding and advocacy programs and services and works toward creating a world without multiple sclerosis (MS). Coetzee…

Kesimpta (ofatumumab) is more effective than Aubagio (teriflunomide) among people with multiple sclerosis (MS) from ethnically diverse groups, including Black and African American, Hispanic and Latino, and Asian individuals, according to an analysis of pooled clinical trial data. “Determining whether there are differences in how people respond…

Immutep has been cleared to start a Phase 1 clinical trial in the Netherlands to test IMP761, its experimental antibody therapy for autoimmune diseases such as multiple sclerosis (MS), in healthy volunteers. The first-in-human Phase 1 clinical trial seeks to assess the safety and pharmacological properties of IMP761.

Using machine learning to analyze eye scans can help detect slight changes that may be early signs of multiple sclerosis (MS), potentially aiding in early diagnosis of the disease, a study found. The study, “SLO-Net: Enhancing Multiple Sclerosis Diagnosis Beyond Optical Coherence Tomography Using Infrared Reflectance…

Treatment with modafinil, a stimulant approved in the U.S. for treating certain sleep-related disorders, significantly reduced fatigue and improved overall quality of life when used in clinical trials for people with multiple sclerosis (MS), according to a review of published study data. However, its use was linked to a…

A PhD student at the UMass Chan Medical School will use funding from a newly awarded fellowship to advance his research into the mechanisms used by cells to repair myelin, the protective sheath around nerve cells that’s damaged in multiple sclerosis (MS) and other demyelinating conditions. The ongoing…

Levels of the immune cell protein CHIT1 at diagnosis, taken from the spinal fluid via a spinal tap, may strongly predict how fast disability progression will occur in people with multiple sclerosis (MS), a new study suggests. Compared with standard clinical measures used to predict disease progression — such…

People with multiple sclerosis (MS) tend to experience a short-term reduction in disability and brain lesion volume after receiving stem cell therapy, according to a meta-analysis of nine studies detailing randomized clinical trials. After six and 12 months, however, the researchers found no differences in disability between patients…

Multiple sclerosis (MS) patients exhibited greater resistance to the effects of insulin — the hormone responsible for keeping the body’s blood sugar levels within a healthy range — and had higher overall insulin levels compared with people without the neurodegenerative disease, a meta-analysis of published studies found. These findings…

Using a newly developed molecular analysis, a research team has discovered previously unknown subsets of immune cells and genes that may play a role in multiple sclerosis (MS) and other immune-mediated diseases. “We discovered new types of helper T cells as well as genes related to immune disorders. We…

A subcutaneous, or under-the-skin, formulation of Ocrevus (ocrelizumab) received approval from the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) to treat adults with multiple sclerosis (MS). The approval means that people with relapsing forms of MS and those with primary progressive MS (PPMS) will now be…

Abata Therapeutics is expected to launch a Phase 1 clinical trial by the end of the year to test ABA-101, its experimental therapy for progressive multiple sclerosis (MS), after getting a green light from the U.S. Food and Drug Administration (FDA). The FDA approved Abata’s investigational new drug…

Methylphenidate, a stimulant sometimes used to manage fatigue in multiple sclerosis (MS), may also ease oculomotor (eye movement) symptoms and increase how quickly the brain processes visual information, according to a pilot study by Kessler Foundation in New Jersey. “Our findings suggest that methylphenidate could be a beneficial…

Can Do Multiple Sclerosis is putting together a two-day program to help newly or recently diagnosed patients and their caregivers learn more about multiple sclerosis (MS), meet others with the disease, and find strategies to adapt to a new lifestyle. Called Take Charge, the free program will…

The Australian government’s Medical Research Future Fund (MRFF) has awarded AU$2.9 million (about $1.96 million) to support a project focused on developing artificial intelligence (AI) precision medicine strategies for multiple sclerosis (MS). The project will be conducted by a team of investigators that will include neurologists, neuroradiologists, and data…

Nearly one year of treatment with frexalimab, an antibody being developed by Sanofi, significantly reduced the blood levels of neurofilament light chain (NfL), a biomarker of nerve cell damage that typically is elevated in people with multiple sclerosis (MS). That’s according to new data from a company-sponsored…

A panel of 20 proteins in blood may be used to quantify disease activity, namely relapses and lesions, in people with multiple sclerosis (MS), a new paper proposes. “A multi-protein panel like the one developed in this study has the capability to capture the state of a patient’s MS…

The U.S Food and Drug Administration (FDA) authorized an investigational new drug application from Synaptogenix, clearing the company to launch a clinical trial to test whether its lead candidate bryostatin-1 can prevent cognitive decline in people with multiple sclerosis (MS). The open-label, Phase 1 clinical trial (NCT06190912),…

Measures associated with how well individuals can modulate their backward walking speed could be used as a screening tool for mobility and cognition problems in people with multiple sclerosis (MS), according to a study by Michigan researchers. A diminished ability to alter walking speed on demand correlated with worse…

Bit.bio, a company that creates human-derived cell products, has launched a novel product called ioAstrocytes, which provides functional human astrocytes to help scientists model the brain and study neurological disease mechanisms or screen new drugs. Astrocytes are star-shaped cells in the brain and spinal cord that provide support…

When given a specific set of chemical cues, immune cells called neutrophils are able to take on healing abilities that allow them to help repair damaged nerve fibers, a study by U.S. researchers found. The researchers hope to build on this discovery to create new treatments for multiple sclerosis…

Researchers have identified characteristics of regulatory T-cells (Tregs) — a family of immune cells that help keep harmful immune reactions in check — that could make it easier to develop targeted treatments for autoimmune conditions like multiple sclerosis (MS). They found that Tregs exist as a common pool that…

Two inverse vaccines from Nykode Therapeutics — developed to teach the immune system not to respond against its own body — worked to reduce disease severity in a mouse model of multiple sclerosis (MS), new data show. This adds to earlier findings that the company’s experimental approach and…

The European Commission has approved a subcutaneous, or under-the-skin, formulation of Ocrevus (ocrelizumab) to treat adults with multiple sclerosis (MS). The approval makes the new formulation available in the European Union for the same indications as the original intravenous (into-the-vein) formulation, which is available to people with relapsing…

People with multiple sclerosis (MS) who have cognitive impairment tend to report worse mental and physical quality of life than patients who don’t have cognitive issues, a study reports. Adults with MS who have cognitive problems are also less likely to be employed. The study, “Association…

Cionic has added three renowned institutions on the East Coast to its national Centers of Excellence program, a move that expands the availability in the U.S. of the Neural Sleeve to people with multiple sclerosis (MS) and other neurological conditions that affect mobility. The program represents a key…

Siemens Healthineers has received the CE mark in Europe for a lab-based blood test that measures the levels of neurofilament light chain, known as NfL — a protein that gets released into the bloodstream upon damage to nerve cells — in adults with relapsing forms of multiple sclerosis…